Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin for Endotoxemia in Cirrhosis
NCT06630572Phase 4Terminated
- Sponsor
- Sapienza University of Rome
- Start
- Apr 2021
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Liver cirrhosis (LC) and endotoxemia comparing Rifaximin with Placebo (2 arms). Primary endpoint: Decrease in serum endotoxemia at 60 days. Started Apr 2021; status: terminated.
02
Drugs
rifaximin
03
Conditions
Liver cirrhosis (LC)endotoxemia
Beyond the preview
Go deeper on NCT06630572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06630572.